Marksans Pharma Limited Stock Price Today (NSE: MARKSANS)
Fundamental Score
Marksans Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Marksans Pharma Limited share price today is ₹316.45, up +1.15% on NSE/BSE as of 16 September 2026. Marksans Pharma Limited (MARKSANS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹14.34K (Cr). The 52-week high for MARKSANS share price is ₹349.95 and the 52-week low is ₹155.00. At a P/E ratio of 27.73x, MARKSANS is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 25.56% and a debt-to-equity ratio of 0.01.
Marksans Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Marksans Pharma Limited share price chart: 21.62% return over the past month. 52-week high ₹349.95, 52-week low ₹155.00.
Marksans Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹311.80 | ₹323.60 | ₹307.05 | ₹316.45 | 22.64L (Cr) | |
| ₹330.00 | ₹331.40 | ₹301.10 | ₹312.85 | 22.98L (Cr) | |
| ₹325.00 | ₹333.75 | ₹324.20 | ₹329.40 | 16.32L (Cr) | |
| ₹329.00 | ₹334.55 | ₹323.80 | ₹330.40 | 12.95L (Cr) | |
| ₹336.00 | ₹340.00 | ₹328.65 | ₹330.15 | 17.84L (Cr) | |
| ₹337.50 | ₹349.95 | ₹331.60 | ₹335.90 | 50.90L (Cr) | |
| ₹327.50 | ₹339.00 | ₹326.75 | ₹335.05 | 27.98L (Cr) | |
| ₹333.00 | ₹335.45 | ₹323.45 | ₹326.75 | 16.54L (Cr) | |
| ₹334.30 | ₹341.00 | ₹331.00 | ₹332.20 | 27.26L (Cr) | |
| ₹321.20 | ₹337.65 | ₹318.75 | ₹332.50 | 65.73L (Cr) |
Marksans Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹322.90 | ₹349.95 | ₹301.10 | ₹316.45 | -2.00% | |
| ₹259.00 | ₹345.50 | ₹258.85 | ₹321.60 | +24.17% | |
| ₹274.40 | ₹281.60 | ₹242.40 | ₹258.35 | -5.85% | |
| ₹249.00 | ₹277.00 | ₹228.20 | ₹272.81 | +9.56% | |
| ₹184.63 | ₹264.40 | ₹184.63 | ₹246.19 | +33.34% | |
| ₹165.00 | ₹195.68 | ₹160.60 | ₹184.63 | +11.90% | |
| ₹165.00 | ₹178.00 | ₹155.00 | ₹156.89 | -4.92% | |
| ₹168.51 | ₹191.74 | ₹161.70 | ₹173.93 | +3.22% | |
| ₹181.80 | ₹187.26 | ₹156.00 | ₹163.85 | -9.87% | |
| ₹188.10 | ₹197.80 | ₹175.64 | ₹180.29 | -4.15% | |
| ₹180.51 | ₹201.30 | ₹179.80 | ₹187.95 | +4.12% | |
| ₹166.00 | ₹186.72 | ₹162.00 | ₹182.08 | +9.69% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Marksans Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Marksans Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MARKSANS across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (25.56%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (32.39%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (21.08%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 27.73 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (169.50%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (35.61%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (16.48% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (24.24x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 4.62)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹619.62 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
High Price-to-Book Ratio (5.81x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Marksans Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Marksans Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Marksans Pharma LimitedMarksans Pharma...Selected✓ MARKSANS • 524404 | 68.7/100 | ₹316.45₹316 | ₹14340.25₹14340.25 | 27.73Average 27.7 Average | 25.56%Excellent 25.56% Excellent | 32.39%Excellent 32.39% Excellent | 0.01Excellent 0.0 Excellent | 11.87%Good 11.87% Good | 16.48%Excellent 16.48% Excellent | 0.29% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Marksans Pharma Limited PE Ratio History
Historical price-to-earnings ratio for MARKSANS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.40 | ₹180.29 | 21.5x |
| FY 2024 | ₹6.92 | ₹296.65 | 42.9x |
| FY 2023 | ₹6.41 | ₹161.10 | 25.1x |
| FY 2022 | ₹4.51 | ₹58.25 | 12.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Marksans Pharma Limited Dividend History
Annual cash dividends paid by MARKSANS — dividend yield 0.29%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹27.19 Cr |
| FY 2024 | ₹22.66 Cr |
| FY 2023 | ₹10.17 Cr |
| FY 2022 | ₹10.58 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Marksans Pharma Limited Quarterly Performance
Latest quarterly metrics for MARKSANS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
35.61%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
169.50%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
16.48%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
11.87%
Compounded annual net profit growth over 5 years
Marksans Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MARKSANS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Marksans Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Marksans Pharma Limited (MARKSANS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Marksans Pharma Limited
About MARKSANS (Marksans Pharma Limited)
Marksans Pharma Ltd is a globally oriented pharmaceutical company carving a niche for itself through focused research, rigorous manufacturing standards, and strategic marketing ini...tiatives. They operate across multiple continents, reaching patients in the United States, Europe, Australia, and beyond. Their success stems from a dedication to producing reliable and accessible pharmaceutical formulations, addressing a wide spectrum of health needs. Marksans distinguishes itself by cultivating strong relationships with regulatory bodies and consistently adapting to evolving market demands, ensuring its products remain both compliant and relevant. Through continuous innovation and a commitment to quality, they strive to improve healthcare outcomes on a global scale, solidifying their position as a trusted provider of pharmaceutical solutions. Marksans’ diverse portfolio reflects its commitment to addressing prevalent health challenges worldwide. Their product offerings span a comprehensive range of therapeutic areas, including treatments for pain management, cardiovascular health, neurological disorders, and metabolic conditions. They also provide essential medications for gastrointestinal issues, respiratory ailments, and dermatological conditions, as well as specialized therapies for oncology, allergies, and viral infections. This broad scope allows Marksans to cater to the varied needs of healthcare professionals and patients, ensuring access to vital medications. Furthermore, their dedication extends to preventative care, with a focus on dietary supplements designed to support overall well-being. Marksans’ success hinges on a vertically integrated approach, encompassing every stage from research and development to manufacturing and distribution. Their state-of-the-art manufacturing facilities adhere to the highest international quality standards, ensuring the safety and efficacy of their products. By maintaining strict control over the entire production process, they can guarantee consistency and reliability. Marksans also invests significantly in research and development, fostering innovation and driving the development of new and improved formulations. This commitment to excellence and continuous improvement positions them as a dynamic and forward-thinking player in the pharmaceutical industry.
Company Details
Key Leadership
MARKSANS Share Price: Frequently Asked Questions
What is the current share price of Marksans Pharma Limited?
Marksans Pharma Limited (MARKSANS) trades at ₹316.45 on NSE and BSE. Market cap ₹14.34K (Cr). Educational data only.
What is the P/E ratio of Marksans Pharma Limited?
Marksans Pharma Limited has a P/E of 27.73x vs industry average 34.89x.
What is the Bull Run score for Marksans Pharma Limited?
Marksans Pharma Limited has a Bull Run score of 68.7/100 based on 25+ financial parameters.
Does Marksans Pharma Limited pay dividends?
Marksans Pharma Limited has a dividend yield of 0.29%. Past dividends don't guarantee future payments.
What is the ROE of Marksans Pharma Limited?
Marksans Pharma Limited has ROE of 25.56%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Marksans Pharma Limited?
Marksans Pharma Limited has debt-to-equity of 0.01.
Is Marksans Pharma Limited a good investment?
Bull Run gives Marksans Pharma Limited a score of 68.7/100. This is not investment advice — consult a SEBI-registered advisor.